Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)

Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)

Updated HCV clinical guidelines placed direct acting agents (DAAs) as the preferable the first line regimens.The objective of the study was PE assessment of HCV therapy among G1 naïve patientsMethods: Analysis is based on data of randomized clinical trials and average price of HCV medicines from sta...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Rudakova, D. A. Gusev, A. N. Uskov, Yu. V. Lobzin
Format:	Article
Language:	Russian
Published:	Journal Infectology 2016-02-01
Series:	Журнал инфектологии
Subjects:	chronic hepatitis c genotype 1 naïve patients direct acting agents cost effectiveness
Online Access:	https://journal.niidi.ru/jofin/article/view/450
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01)

COST-EFFECTIVENESS OF ANTIVIRAL THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C (GENOTYPE 1) WITH VARIOUS SEVERITY OF FIBROSIS STAGE
by: A. V. Rudakova, et al.
Published: (2018-01-01)

Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease
by: A. V. Rudakova, et al.
Published: (2016-04-01)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01)

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
by: A. V. Rudakova, et al.
Published: (2017-04-01)

Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness
by: A. V. Rudakova, et al.
Published: (2015-04-01)

Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?
by: Zhitao Wang, et al.
Published: (2025-07-01)

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature
by: Olga H. Orasan, et al.
Published: (2019-10-01)

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up
by: S. V. Gavrisheva, et al.
Published: (2023-04-01)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
by: Sarah R. Donaldson, et al.
Published: (2025-01-01)

New drugs in the treatment of chronic hepatitis C
by: R. Jimenez Galan, et al.
Published: (2014-04-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
by: Carlo Smirne, et al.
Published: (2024-12-01)

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
by: Ioana Adela Ratiu, et al.
Published: (2024-12-01)

Sorafenib-treated hepatocellular carcinoma with or without prior direct-acting antiviral therapy for hepatitis C: outcomes and survival
by: Rania Lithy, et al.
Published: (2025-08-01)

Effects of Various Direct-acting Antivirals in the Quality of Life of Patients with Chronic Hepatitis C
by: Hatun ÖZTÜRK ÇERİK, et al.
Published: (2021-12-01)

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
by: Chen-Hua Liu, et al.
Published: (2025-04-01)

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients
by: Sonia Younas, et al.
Published: (2021-10-01)

Liver cirrhosis as a result of chronic hepatitis C
by: A. A. Sukhoruk, et al.
Published: (2014-09-01)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024-11-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

Knowledge among patients with Hepatitis C initiating on direct-acting antiviral treatment in rural Rwanda: A prospective cohort study
by: Dale A Barnhart, et al.
Published: (2021-01-01)

A cross-sectional study of real life data of HCV from Turkey south region
by: Bedia Mutay Suntur, et al.
Published: (2020-04-01)

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6
by: D. A. Lioznov, et al.
Published: (2017-04-01)

Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers
by: Jonathan Hallett, et al.
Published: (2025-05-01)

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy
by: Xiping Ran, et al.
Published: (2025-02-01)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children
by: Salahuddin Mahmud, et al.
Published: (2025-06-01)

Pharmacological interactions in novel oral anticoagulants, statins, and hypertension drugs in patients treated with direct-acting antivirals for hepatitis C: a Delphi Consensus project
by: Ivan Gentile, et al.
Published: (2024-11-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

Incidence and Factors of Hepatocellular Carcinoma in Hepatitis C Virus Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Treatment
by: Juferdy Kurniawan Kurniawan, et al.
Published: (2024-12-01)

Large-scale hepatitis C combating campaigns in Egypt and Georgia; past, current and future challenges
by: Fatma Abdelaziz Amer
Published: (2018-06-01)

Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents
by: N. V. Dunaeva, et al.
Published: (2018-12-01)

Clinical and immunomorphological predictors of the adverse course of chronic hepatitis C
by: I. A. Karabak, et al.
Published: (2020-06-01)

VIRAL HEPATITIS C – GLOBAL HEALTH PROBLEM
by: Kalina Terzieva, et al.
Published: (2025-02-01)

HCV-related chronic kidney disease in the era of new direct-acting antivirals regimens
by: Jakub Janczura, et al.
Published: (2025-08-01)

Problematic issues of the effectiveness of treatment of patients with chronic viral hepatitis C according to the State program and the ways of their solution.
by: L. R. Shostakovych-Koretska, et al.
Published: (2018-11-01)

Genotypic Diversity of Hepatitis C Virus in Tuberculosis Patients in the Tomsk Region
by: K. A. Svirin, et al.
Published: (2025-03-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

The influence of hepatic steatosis on the success of antiviral therapy for chronic hepatitis C
by: Preveden Tomislav, et al.
Published: (2017-01-01)